Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 6/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6256359 | 0.86 | CYP1A2 (0.56) | CYP1A2CYP3A4ALDH1A1SLC6A3SLC6A2 | |
| SCHEMBL4389588 | 0.82 | CYP1A2 (0.53) | CYP1A2CYP3A4ALDH1A1SLC6A3SLC6A2 | |
| SCHEMBL11832284 | 0.81 | CYP1A2 (0.51) | CYP1A2CYP3A4ALDH1A1SLC6A3SLC6A2 | |
| SCHEMBL4389584 | 0.81 | CYP3A4 (0.60) | CYP1A2CYP3A4ALDH1A1SLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL11193599 | 0.79 | CYP1A2 (0.50) | CYP1A2CYP3A4ALDH1A1SLC6A3SLC6A2 | |
| SCHEMBL11195298 | 0.78 | CYP1A2 (0.49) | CYP1A2CYP3A4ALDH1A1SLC6A3SLC6A2 | |
| SCHEMBL18601246 | 0.77 | KCNA5 (0.44) | CYP1A2CYP3A4ALDH1A1SLC6A3SLC6A2 | |
| SCHEMBL27536605 | 0.76 | CYP1A2 (0.64) | CYP1A2CYP3A4ALDH1A1SLC6A3SLC6A2 | |
| SCHEMBL289900 | 0.75 | CYP1A2 (0.53) | CYP1A2CYP3A4ALDH1A1SLC6A3SLC6A2 | |
| SCHEMBL24239786 | 0.74 | CYP3A4 (0.53) | CYP1A2CYP3A4ALDH1A1SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-03-10 | — | — | US | claimed |
| EP-4684872-A1 | DEVICE AND METHOD FOR WATER-IN-AIR GENERATION OF DROPLETS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-01-28 | — | — | EP | claimed |
| US-20230181466-A1 | BOTTOM-UP ASSEMBLY OF SYNTHETIC EXTRACELLULAR VESICLES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-06-15 | — | — | US | claimed |
| EP-4164693-A1 | NANOLIPOPROTEIN-POLYPEPTIDE CONJUGATES AND COMPOSITIONS, SYSTEMS, AND METHODS USING SAME | Genentech, Inc. (US) | 2023-04-19 | — | — | EP | claimed |
| US-20230038598-A1 | MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED CARGO DELIVERY | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-02-09 | — | — | US | claimed |
| US-11446238-B2 | Injectable dendrimer hydrogel nanoparticles | WAYNE STATE UNIVERSITY (US) | 2022-09-20 | — | — | US | claimed |
| EP-4054533-A1 | BOTTOM-UP ASSEMBLY OF SYNTHETIC EXTRACELLULAR VESICLES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-09-14 | — | — | EP | claimed |
| EP-4054532-A1 | MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED CARGO DELIVERY | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-09-14 | — | — | EP | claimed |
| WO-2021252803-A1 | NANOLIPOPROTEIN-POLYPEPTIDE CONJUGATES AND COMPOSITIONS, SYSTEMS, AND METHODS USING SAME | GENENTECH, INC. (US) | 2021-12-16 | — | — | WO | claimed |
| WO-2021152115-A1 | BOTTOM-UP ASSEMBLY OF SYNTHETIC EXTRACELLULAR VESICLES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-08-05 | — | — | WO | claimed |
| EP-1813614-B1 | Cytotoxic agents comprising new tomaymycin derivatives | SANOFI SA (FR) | 2011-10-05 | — | — | EP | claimed |
| US-20100092567-A1 | IMMUNOSTIMULATORY NANOPARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2010-04-15 | — | — | US | claimed |
| US-20090311276-A1 | NANOLIPOPROTEIN PARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC | 2009-12-17 | — | — | US | claimed |
| WO-2009143280-A2 | NANOLIPOPROTEIN PARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2009-11-26 | — | — | WO | claimed |
| EP-0550663-B1 | MODIFIED ANTIBODIES WITH CONTROLLED CLEARANCE TIME | TECHNICLONE INC (US) | 1998-01-21 | — | — | EP | claimed |
| EP-0783894-A1 | Antibodies modified at two separate sites | TECHNICLONE, INC. (US) | 1997-07-16 | — | — | EP | claimed |
| EP-0339264-B1 | Compounds for the introduction of a mercapto group to tyrosin | BOEHRINGER MANNHEIM GMBH (DE) | 1994-08-03 | — | — | EP | claimed |
| EP-0252951-A4 | TECHNETIUM-ANTIBODY CONJUGATE. | UNIV MELBOURNE (AU) | 1988-09-07 | — | — | EP | claimed |
| EP-0252951-A1 | TECHNETIUM-ANTIBODY CONJUGATE | THE UNIVERSITY OF MELBOURNE (AU) | 1988-01-20 | — | — | EP | claimed |
| WO-1987004164-A1 | TECHNETIUM-ANTIBODY CONJUGATE | THE UNIVERSITY OF MELBOURNE (AU) | 1987-07-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230038598-A1 | MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED CARGO DELIVERY | PCNA, BOD1L1, SARS1 | CYP1A2 4775/4885CYP3A4 4442/4885ALDH1A1 3690/4885 |
| US-11446238-B2 | Injectable dendrimer hydrogel nanoparticles | PAM, UACA, FLT1 | CYP1A2 3241/4885CYP3A4 3080/4885ALDH1A1 1885/4885 |
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | EXOSC10, PLTP, EXOSC9 | CYP1A2 4873/4885CYP3A4 4871/4885ALDH1A1 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.